High-yield production of canine parvovirus virus-like particles in a baculovirus expression system

详细信息    查看全文

• 作者：Hongli Jin ; Xiaohong Xia ; Bing Liu ; Yu Fu ; Xianping Chen…
• 关键词：Canine parvovirus ; Virus ; like particles ; Vaccine
• 刊名：Archives of Virology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：161
• 期：3
• 页码：705-710
• 全文大小：3,343 KB
• 参考文献：1.Airenne KJ, Hu YC, Kost TA, Smith RH, Kotin RM, Ono C, Matsuura Y, Wang S, Yla-Herttuala S (2013) Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther 21:739–749PubMedCentral CrossRef PubMed
  2.Buonavoglia C, Compagnucci M, Orfei Z (1983) Dog response to plaque variant of canine parvovirus. Zentralbl Veterinarmed B 30:526–531CrossRef PubMed
  3.Calderon MG, Mattion N, Bucafusco D, Fogel F, Remorini P, La Torre J (2009) Molecular characterization of canine parvovirus strains in Argentina: detection of the pathogenic variant CPV2c in vaccinated dogs. J Virol Methods 159:141–145CrossRef PubMed
  4.Casal JI (1999) Use of parvovirus-like particles for vaccination and induction of multiple immune responses. Biotechnol Appl Biochem 29(Pt 2):141–150PubMed
  5.Cavalli A, Bozzo G, Decaro N, Tinelli A, Aliberti A, Buonavoglia D (2001) Characterization of a canine parvovirus strain isolated from an adult dog. New Microbiol 24:239–242PubMed
  6.Cavalli A, Martella V, Desario C, Camero M, Bellacicco AL, De Palo P, Decaro N, Elia G, Buonavoglia C (2008) Evaluation of the antigenic relationships among canine parvovirus type 2 variants. Clin Vaccine Immunol 15:534–539PubMedCentral CrossRef PubMed
  7.Crisci E, Barcena J, Montoya M (2012) Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 148:211–225CrossRef PubMed
  8.Decaro N, Desario C, Elia G, Martella V, Mari V, Lavazza A, Nardi M, Buonavoglia C (2008) Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c. New Microbiol 31:125–130PubMed
  9.Elia G, Desario C, Pezzoni G, Camero M, Brocchi E, Decaro N, Martella V, Buonavoglia C (2012) Recombinant ELISA using baculovirus-expressed VP2 for detection of antibodies against canine parvovirus. J Virol Methods 184:98–102CrossRef PubMed
  10.Feng H, Hu GQ, Wang HL, Liang M, Liang H, Guo H, Zhao P, Yang YJ, Zheng XX, Zhang ZF, Zhao YK, Gao YW, Yang ST, Xia XZ (2014) Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity. PLoS One 9:e79575PubMedCentral CrossRef PubMed
  11.Gil F, Brun A, Wigdorovitz A, Catala R, Martinez-Torrecuadrada JL, Casal I, Salinas J, Borca MV, Escribano JM (2001) High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Lett 488:13–17CrossRef PubMed
  12.Gil F, Reytor E, Perez-Filgueira DM, Escribano JM (2007) Multimerization of peptide antigens for production of stable immunogens in transgenic plants. J Biotechnol 128:512–518CrossRef PubMed
  13.Graf M, Bojak A, Deml L, Bieler K, Wolf H, Wagner R (2000) Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J Virol 74:10822–10826PubMedCentral CrossRef PubMed
  14.Gustafsson C, Govindarajan S, Minshull J (2004) Codon bias and heterologous protein expression. Trends Biotechnol 22:346–353CrossRef PubMed
  15.Hu YC, Yao K, Wu TY (2008) Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines 7:363–371CrossRef PubMed
  16.Ikemura T (1981) Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein genes. J Mol Biol 146:1–21CrossRef PubMed
  17.Luckow VA (1993) Baculovirus systems for the expression of human gene products. Curr Opin Biotechnol 4:564–572CrossRef PubMed
  18.Madhan S, Prabakaran M, Kwang J (2010) Baculovirus as vaccine vectors. Curr Gene Ther 10:201–213CrossRef PubMed
  19.Martella V, Cavalli A, Decaro N, Elia G, Desario C, Campolo M, Bozzo G, Tarsitano E, Buonavoglia C (2005) Immunogenicity of an intranasally administered modified live canine parvovirus type 2b vaccine in pups with maternally derived antibodies. Clin Diagn Lab Immunol 12:1243–1245PubMedCentral PubMed
  20.Pollock RV, Carmichael LE (1982) Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc 180:37–42PubMed
  21.Pollock RV, Carmichael LE (1982) Dog response to inactivated canine parvovirus and feline panleukopenia virus vaccines. Cornell Vet 72:16–35PubMed
  22.Pratelli A, Cavalli A, Martella V, Tempesta M, Decaro N, Carmichael LE, Buonavoglia C (2001) Canine parvovirus (CPV) vaccination: comparison of neutralizing antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccine. Clin Diagn Lab Immunol 8:612–615PubMedCentral PubMed
  23.Saliki JT, Mizak B, Flore HP, Gettig RR, Burand JP, Carmichael LE, Wood HA, Parrish CR (1992) Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol 73(Pt 2):369–374CrossRef PubMed
  24.Tokuoka M, Tanaka M, Ono K, Takagi S, Shintani T, Gomi K (2008) Codon optimization increases steady-state mRNA levels in Aspergillus oryzae heterologous gene expression. Appl Environ Microbiol 74:6538–6546PubMedCentral CrossRef PubMed
  25.Truyen U (2006) Evolution of canine parvovirus—a need for new vaccines? Vet Microbiol 117:9–13CrossRef PubMed
  26.Yi L, Tong M, Cheng Y, Song W, Cheng S (2014) Phylogenetic analysis of canine parvovirus VP2 gene in China. Transbound Emerg Dis. doi:10.​1111/​tbed.​12268
  27.Yuan W, Parrish CR (2001) Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 279:546–557CrossRef PubMed
  28.Zhang R, Yang S, Zhang W, Zhang T, Xie Z, Feng H, Wang S, Xia X (2010) Phylogenetic analysis of the VP2 gene of canine parvoviruses circulating in China. Virus Genes 40:397–402CrossRef PubMed
  29.Zhi N, Wan Z, Liu X, Wong S, Kim DJ, Young NS, Kajigaya S (2010) Codon optimization of human parvovirus B19 capsid genes greatly increases their expression in nonpermissive cells. J Virol 84:13059–13062PubMedCentral CrossRef PubMed
  
• 作者单位：Hongli Jin (1)
  Xiaohong Xia (1)
  Bing Liu (1)
  Yu Fu (1)
  Xianping Chen (1)
  Huihui Wang (1)
  Zhenqiang Xia (1)
  
  1. Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Virology
  Medical Microbiology
  Infectious Diseases
  
• 出版者：Springer Wien
• ISSN：1432-8798

文摘

An optimized VP2 gene from the current prevalent CPV strain (new CPV-2a) in China was expressed in a baculovirus expression system. It was found that the VP2 proteins assembled into virus-like particles (VLPs) with antigenic properties similar to those of natural CPV and with an especially high hemagglutination (HA) titer (1:220). Dogs intramuscularly or orally immunized with VLPs produced antibodies against CPV with >1:80 hemagglutination inhibition (HI) units for at least 3 months. The CPV VLPs could be considered for use as a vaccine against CPV or as a platform for research on chimeric VLP vaccines against other diseases.